Citigroup
PRME icon

Citigroup’s Prime Medicine PRME Stock Holding History

Citigroup’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$511K Sell
167,328
-28,336
-14% -$94.1K ﹤0.01% 3748
2026
Q2 		$722K Buy
195,664
+148,432
+314% +$493K ﹤0.01% 3683
2026
Q1 		$164K Sell
47,232
-3,997
-8% -$15.2K ﹤0.01% 4080
2025
Q4 		$178K Buy
51,229
+46,078
+895% +$205K ﹤0.01% 4058
2025
Q3 		$28.5K Sell
5,151
-29,608
-85% -$120K ﹤0.01% 4687
2025
Q2 		$85.9K Sell
34,759
-7,543
-18% -$11.6K ﹤0.01% 4484
2025
Q1 		$84.2K Sell
42,302
-5,129
-11% -$13.1K ﹤0.01% 4688
2024
Q4 		$138K Sell
47,431
-640
-1% -$2.25K ﹤0.01% 4657
2024
Q3 		$186K Buy
48,071
+30,560
+175% +$142K ﹤0.01% 4388
2024
Q2 		$90K Sell
17,511
-26,459
-60% -$160K ﹤0.01% 4264
2024
Q1 		$308K Buy
43,970
+33,035
+302% +$251K ﹤0.01% 3826
2023
Q4 		$96.9K Sell
10,935
-45,258
-81% -$349K ﹤0.01% 4215
2023
Q3 		$536K Buy
56,193
+42,032
+297% +$546K ﹤0.01% 3005
2023
Q2 		$207K Buy
14,161
+5,302
+60% +$74K ﹤0.01% 3882
2023
Q1 		$109K Buy
8,859
+5,272
+147% +$85.9K ﹤0.01% 3980
2022
Q4 		$66.6K Buy
+3,587
New +$64.8K ﹤0.01% 4187

Other funds holding PRME

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Alessandra Capital Management
Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Pekin Hardy Strauss
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 25.53% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.95% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup's PRME Position: Q3 2026 in Review

Citigroup reduced its Prime Medicine (PRME) stake by 14% in Q3 2026, selling an estimated $94.1K and leaving 167,328 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #3748.

Citigroup first reported a position in PRME in Q4 2022 and has held it in 16 quarters since. The position peaked at $722K in Q2 2026. 46 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Citigroup held 167,328 shares of Prime Medicine worth $511K as of Q3 2026.
  • Citigroup sold 28,336 Prime Medicine shares in Q3 2026, an estimated $94.1K.
  • Prime Medicine made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3748 holding.
  • Citigroup first reported a position in Prime Medicine in Q4 2022 and has held it in 16 quarters since.
  • Citigroup's Prime Medicine position peaked at $722K in Q2 2026.
  • 46 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.